News and Announcements
Phylogica Limited (ASX: PYC) set to reach experimental milestone
- Published July 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phylogica Limited (ASX: PYC) is expected to complete their experience of delivering Cre Cargo into the nucleus cells in multiple tissues in live animals.
- The success of the delivery will represent a significant milestone for the company, transitioning them from proof of concept to therapeutic cargoes.
Phylogica (ASX: PYC) has announced that their experimental timelines are on track. The company will deliver the Cre cargo (enzyme) into the nucleus cells in multiple tissues in a live animal in July 2018. Phylogica’s core asset is their structurally diverse drug library which the company has chosen to use in identifying Cell Penetrating Peptides (CPPs). The successful delivery of the Cre cargo in the animal experiments will be a significant milestone for the company and help with the commercial validation of the company’s biological peptides. It will enable the transition for proof of concept stage of validating their platform to the testing of therapeutic drug cargoes.
The company has an opportunity to improve their attractiveness of the platform by delivering a cargo class of interest into a target cell more efficiently than competitive technology. The company’s original CPP has already successfully delivered Cre into kidney cells. The company has also commenced further screening of their re-populated libraries to identify additional CPPs and has gained strong interest from biotech companies who are looking for effective delivery platforms for their developed drug cargoes.
About Phylogica Limited (ASX: PYC)
Phylogica’s drug delivery platform harnesses the power of viruses and bacteria for good. These organisms have long been known to cross the cell wall to where the highest value drug targets reside. Phylogica’s delivery technology uses their genetic secrets to take drug cargoes where they cannot go alone – unlocking the undruggable genome.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
